a. Thrombin peptide TP508 stimulates rapid nitric oxide production in human endothelial cells. Olszewska-Pazdrak B, Hart-Vantassell A, Carney DH. J Vasc Res. 2010;47(3):203-13. doi: 10.1159/000255963. Epub 2009 Nov 6.PMID: 19893317 https://pubmed.ncbi.nlm.nih.gov/19893317/
b. Systemic administration of thrombin peptide TP508 enhances VEGF-stimulated angiogenesis and attenuates effects of chronic hypoxia. Olszewska-Pazdrak B, Carney DH.J Vasc Res. 2013;50(3):186-96. doi: 10.1159/000348250. Epub 2013 Apr 16. PMID: 23594718 https://pubmed.ncbi.nlm.nih.gov/23594718/
c. Thrombin peptide (TP508) promotes adipose tissue-derived stem cell proliferation via PI3 kinase/Akt pathway. Freyberg S, Song YH, Muehlberg F, Alt E. J Vasc Res. 2009;46(2):98-102. doi: 10.1159/000142727. Epub 2008 Jul 7. PMID: 18607113 https://pubmed.ncbi.nlm.nih.gov/23594718/
d. Thrombin peptide, TP508, induces differential gene expression in fibroblasts through a nonproteolytic activation pathway. Sower LE, Payne DA, Meyers R, Carney DH. Exp Cell Res. 1999 Mar 15;247(2):422-31. doi: 10.1006/excr.1998.4372 PMID: 10066370 https://pubmed.ncbi.nlm.nih.gov/10066370/
e. Synthetic peptides bind to high-affinity thrombin receptors and modulate thrombin mitogenesis. Glenn KC, Frost GH, Bergmann JS, Carney DH. Pept Res. 1988 Nov-Dec;1(2):65-73. PMID: 2856554 https://pubmed.ncbi.nlm.nih.gov/2856554/
